X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will fund multiple Phase 2 trials in cancer, to evaluate HCW9218, the Company’s injectable, bifunctional fusion protein for reduction of senescence; and a Phase 1b study in an autoimmune disease to evaluate HCW9302, an injectable, IL-2-based fusion compound.
Lead Product(s): HCW9218
Therapeutic Area: Oncology Product Name: HCW9218
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Prime Capital Ventures
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 27, 2023
Details:
Preclinical studies in mouse models have demonstrated the ability of HCW9302 to activate Treg cells and reduce inflammation-related disease pathologies, supporting the potential of HCW9302 to treat a wide variety of autoimmune and proinflammatory diseases.
Lead Product(s): HCW9302
Therapeutic Area: Immunology Product Name: HCW9302
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
HCW9218 is novel bi-functional fusion protein complex administered by injection. It is comprised of a soluble fusion of two human TGFβRII domains, human tissue factor, and human IL-15, and second soluble fusion of two human TGFβRII domains and a sushi domain of human IL-15Rα.
Lead Product(s): HCW9218
Therapeutic Area: Oncology Product Name: HCW9218
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
Preclinical data from in vivo animal studies demonstrated ability of HCW9218, to both enhance anti-tumor efficacy of chemotherapy drugs and diminish their harmful side effects by reducing therapy-induced senescence and eliminating TGF-β and its immunosuppressive effects.
Lead Product(s): HCW9218
Therapeutic Area: Oncology Product Name: HCW9218
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
UM cleared to proceed with clinical trial to evaluate HCW9218, activates IL-15R signaling in various advanced solid tumors, such as breast, ovarian, prostate, and colorectal cancers.
Lead Product(s): HCW9218
Therapeutic Area: Oncology Product Name: HCW9218
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: University of Minnesota
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2022
Details:
HCW9218 is an injectable, fusion protein complex designed to drive bifunctional, anti-tumor activity by activating desired immune responses to attack cancer cells while simultaneously blocking unwanted immunosuppressive activities.
Lead Product(s): HCW9218
Therapeutic Area: Oncology Product Name: HCW9218
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2021
Details:
HCW9218 is a heterodimeric, bifunctional fusion protein complex comprising extracellular domains of the human TGF-β receptor II, as TGF-β trap for TGF-β neutralization, and a human interleukin (IL)-15/IL-15 receptor α complex for immune-cell stimulation.
Lead Product(s): HCW9218
Therapeutic Area: Oncology Product Name: HCW9218
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2021
Details:
HCW9218, a bifunctional fusion protein, displayed strong anti-tumor activity mediated by NK cells and CD8+ T cells, and increased infiltration of NK cells and CD8+ T cells into tumors.
Lead Product(s): HCW9218
Therapeutic Area: Oncology Product Name: HCW9218
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
